Olr1245 inhibitors are a specific class of chemical compounds designed to target the Olr1245 receptor, which is a member of the olfactory receptor family within the G protein-coupled receptor (GPCR) superfamily. These receptors are integral to the olfactory system, responsible for detecting and processing a wide range of odorant molecules, ultimately contributing to the sense of smell. Olr1245 inhibitors function by binding to the receptor's active site or other crucial regions, effectively blocking the receptor's ability to interact with its natural ligands. This inhibition disrupts the normal conformational changes and subsequent intracellular signaling pathways that would typically be triggered by the binding of an odorant molecule. The development and design of Olr1245 inhibitors are often guided by detailed structural analyses of the receptor, which can be obtained through advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These techniques provide a detailed understanding of the receptor's binding pockets and other key features, allowing for the creation of inhibitors that are both highly specific to the Olr1245 receptor and effective in modulating its activity.
Chemically, Olr1245 inhibitors exhibit a diverse range of structures and properties, reflecting the varied strategies used in their design and synthesis. These inhibitors may include small, lipophilic molecules that are adept at crossing cellular membranes to reach their target receptors within the olfactory system. Alternatively, they may be larger, more complex molecules that require sophisticated synthetic methods to optimize their binding affinity and specificity. The synthesis of Olr1245 inhibitors often involves multiple steps of organic chemistry, including the careful formation of molecular scaffolds and the introduction of functional groups that enhance the compound's ability to interact with the receptor. Once synthesized, these inhibitors undergo rigorous characterization using a variety of analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These methods are employed to ensure the structural integrity, purity, and inhibitory activity of the compounds. The study of Olr1245 inhibitors not only provides valuable insights into the specific mechanisms by which this olfactory receptor functions but also contributes to the broader understanding of GPCR modulation. This research is essential for advancing knowledge of the molecular processes that underlie sensory perception, particularly within the olfactory system, and offers a deeper understanding of how olfactory receptors can be selectively targeted and regulated by small molecules.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Bruton's tyrosine kinase inhibitor, could disrupt B-cell receptor signaling pathways affecting Olr1245. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK inhibitor, potentially influencing cytokine signaling pathways relevant to Olr1245. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
BCL-2 inhibitor, might affect apoptotic pathways potentially relevant to Olr1245. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, could disrupt cell growth and differentiation pathways influencing Olr1245. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Inhibits Bruton's tyrosine kinase, potentially affecting immune response pathways relevant to Olr1245. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Inhibits MET, VEGFR, and AXL kinases, might alter signaling pathways involving Olr1245. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $551.00 | ||
PI3K inhibitor, could impact cell survival and growth pathways affecting Olr1245. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially impacting cell cycle and proliferation pathways relevant to Olr1245. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
PARP inhibitor, might influence DNA damage response mechanisms affecting Olr1245. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $315.00 $1799.00 | ||
mTOR kinase inhibitor, could modulate cell growth and survival pathways impacting Olr1245. | ||||||